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Intronic expansion of the GGGGCC hexanucleotide repeat within the C9ORF72 gene causes frontotemporal dementia and
amyotrophic lateral sclerosis/motor neuron disease in both familial and sporadic cases. Initial reports indicate that this variant
within the frontotemporal dementia/amyotrophic lateral sclerosis spectrum is associated with transactive response DNA binding
protein (TDP-43) proteinopathy. The amyotrophic lateral sclerosis/motor neuron disease phenotype is not yet well characterized.
We report the clinical and pathological phenotypes associated with pathogenic C9ORF72 mutations in a cohort of 563 cases
from Northern England, including 63 with a family history of amyotrophic lateral sclerosis. One hundred and fifty-eight cases
from the cohort (21 familial, 137 sporadic) were post-mortem brain and spinal cord donors. We screened DNA for the C9ORF72
mutation, reviewed clinical case histories and undertook pathological evaluation of brain and spinal cord. Control DNA samples
(n = 361) from the same population were also screened. The C9ORF72 intronic expansion was present in 62 cases [11% of the
cohort; 27/63 (43%) familial, 35/500 (7%) cases with sporadic amyotrophic lateral sclerosis/motor neuron disease]. Disease
duration was significantly shorter in cases with C9ORF72-related amyotrophic lateral sclerosis (30.5 months) compared with
non-C9ORF72 amyotrophic lateral sclerosis/motor neuron disease (36.3 months, P50.05). C9ORF72 cases included both limb
and bulbar onset disease and all cases showed combined upper and lower motor neuron degeneration (amyotrophic lateral
sclerosis). Thus, clinically, C9ORF72 cases show the features of a relatively rapidly progressive, but otherwise typical, variant of
amyotrophic lateral sclerosis associated with both familial and sporadic presentations. Dementia was present in the patient or a
close family member in 22/62 cases with C9ORF72 mutation (35%) based on diagnoses established from retrospective clinical
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case note review that may underestimate significant cognitive changes in late disease. All the C9ORF72 mutation cases showed
classical amyotrophic lateral sclerosis pathology with TDP-43 inclusions in spinal motor neurons. Neuronal cytoplasmic inclu-
sions and glial inclusions positive for p62 immunostaining in non-motor regions were strongly over-represented in the C9ORF72
cases. Extra-motor pathology in the frontal cortex (P5 0.0005) and the hippocampal CA4 subfield neurons (P50.0005) dis-
criminated C9ORF72 cases strongly from the rest of the cohort. Inclusions in CA4 neurons were not present in non-C9ORF72
cases, indicating that this pathology predicts mutation status.
Keywords: amyotrophic lateral sclerosis; C9ORF72; dementia; neurodegeneration
Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration;
MND = motor neuron disease
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neuro-
degenerative disorder affecting the motor neurons in the cerebral
cortex, brainstem and spinal cord. Progressive destruction of
motor neurons leads to a clinical syndrome of muscle weakness,
wasting and paralysis resulting in death typically within 2–3 years.
Only one drug, riluzole, extends survival and its effects are of
modest impact. The understanding of disease pathogenesis is
gradually increasing, particularly in relation to genetically deter-
mined subtypes of ALS (Ferraiuolo et al., 2011), but there is
poor understanding of the basic mechanisms of motor neuron
injury in sporadic ALS.
ALS affects around six people per 100 000 in the UK with
5–10% of cases having familial disease, usually with autosomal
dominant inheritance. Onset is usually in the 6th or 7th decade,
although familial cases frequently have a younger age of onset.
Mutations in a growing number of genes including superoxide
dismutase 1 (SOD1), TAR DNA binding protein (TARDBP), fused
in sarcoma (FUS), valosin-containing protein (VCP), factor-induced
gene 4 (FIG4), angiogenin (ANG), ubiquilin 2 (UBQLN2) and opti-
neurin (OPTN) have been shown to be causative in 30% of
adult-onset familial ALS and in a smaller proportion of sporadic
ALS cases (Ticozzi et al., 2011). In addition, genome-wide associ-
ation studies have identified variants in several other genes,
including ataxin 2 (ATXN2) and UNC13A, that are associated
with increased risk of developing sporadic ALS (Lambrechts
et al., 2003; van Es et al., 2009; Elden et al., 2010).
Understanding how variations in these genes cause motor
neuron degeneration is key to improving our understanding of
disease pathophysiology and to the development of more power-
ful neuroprotective therapies.
In addition to the genes described earlier, genetic linkage to
several other genomic regions, including 9p21 (ALS-FTD), 18q21
(ALS3) and 20p13 (ALS7), has been demonstrated in familial ALS
cases (Ticozzi et al., 2011). The chromosome 9p21 locus has been
intensively investigated in recent years by researchers interested
both in ALS and the related condition frontotemporal dementia
(FTD). This locus was first described in families with a high
proportion of concurrent ALS and FTD (Hosler et al., 2000) and
the locus was more recently refined in ALS cases to a 20 single
nucleotide polymorphism common haplotype spanning a 140-kb
segment (Mok et al., 2011). Linkage to 9p21 has generated
particular interest because it provides strong evidence for the asso-
ciation between ALS and frontotemporal lobar degeneration
(FTLD), which share common neuropathological features and
have significant clinical overlap (Fecto and Siddique, 2011). In
addition, the 9p21 locus was estimated to account for nearly
half of familial ALS cases and one-fifth of sporadic ALS cases in
the Finnish population (Laaksovirta et al., 2010). However, direct
sequencing of the coding regions of the three genes at this locus
(MOBKL2B, C9ORF72 and IFNK) did not reveal any pathogenic
variants.
Two groups have now separately identified the gene associated
with the 9p21 linkage as a GGGGCC hexanucleotide repeat
expansion in intron 1 of the gene C9ORF72 (NM018325.2)
(DeJesus-Hernandez et al., 2011; Renton et al., 2011).
Following demonstration of segregation with ALS in two families,
Renton et al. (2011) subsequently found the expansion in 46.4%
of familial and 21% of sporadic ALS cases in the Finnish cohort
and 38.1% of familial ALS cases from USA, Italy and Germany.
DeJesus-Hernandez et al. (2011) similarly demonstrated segrega-
tion of the C9ORF72 expansion in a large autosomal dominant
ALS/FTD kindred (VSM-20). Subsequent screening of a larger
cohort of FTD and ALS cases identified the expansion in 11.7%
of familial and 3% of sporadic FTD cases, and 23.5% of familial
and 4.1% of sporadic ALS cases. The length of the expansion
varied between 6.5–12 kb (700–1600 repeats), while the majority
of controls contained two repeats.
Neuropathology in both FTLD and ALS cases with C9ORF72
expansions showed TDP-43-positive neuronal and glial inclusions
and a higher proportion of nuclear RNA foci in frontal cortex and
spinal cord neurons. No unique clinical phenotype was associated
with this subtype of ALS or FTD.
We sought to confirm the relevance of this important finding in
a large cohort of patients with ALS/motor neuron disease (MND)
from Northern England, and to investigate clinical and pathological
differences between cases with and without the repeat expansion.
These patients represent a well-characterized cohort of 563 ALS
cases, including 63 familial ALS index cases, with serial clinical
assessment performed every 2–3 months throughout the disease
course. Post-mortem pathological evaluation was available in 28%
of these cases.
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Materials and methods
Cases with amyotrophic lateral sclerosis
and controls
DNA was extracted from 42 familial ALS index cases and 363 patients
with sporadic ALS from the Sheffield MND Blood DNA Biobank.
Additional DNA samples were isolated from 21 familial ALS index
cases and 137 sporadic ALS cases in the Sheffield Brain Tissue Bank.
In total, 563 ALS cases were screened: 63 familial ALS index cases and
500 sporadic ALS cases. Familial ALS cases were defined as individuals
with one or more first or second degree relatives with a confirmed
diagnosis of ALS. All 563 cases were reviewed by a senior consultant
neurologist (C.J.M. or P.J.S.) and diagnosed with definite or probable
ALS, as defined by the El Escorial criteria (Brooks et al., 2000). A full
family history was taken from each patient. Patients with known mu-
tations in SOD1 (n = 14), TARDBP (n = 5), FUS (n = 4), ANG (n = 1),
OPTN (n = 1), charged multi-vesicular protein 2B (CHMP2B) (n = 4)
and vesicle associated membrane protein 2B (VAPB) (n = 1) were
included in the C9ORF72 screening. DNA was extracted from blood
using the NucleonTM Blood and Cell Culture Genomic Extraction kit
(Tepnel) according to the manufacturer’s protocol, while DNA was
extracted from fresh frozen cerebellar samples using the Soft Tissue
DNA Extraction Kit (Tepnel). Control DNA (n = 361) was extracted
from blood donated by partners or unrelated carers of patients with
ALS. All samples were from UK Caucasians. The South Sheffield
Research Ethics Committee approved the study, and informed consent
was obtained for all samples.
Determination of the clinical phenotype
of patients with ALS with the C9ORF72
hexanucleotide expansion
Clinical notes of patients found to carry the C9ORF72 expansion were
reviewed in a systematic fashion to identify details of the disease
phenotype including gender, age of onset, disease duration, disease
variant, details of family history and the presence of any cognitive
impairment. It should be noted that patients in this cohort only under-
went formal cognitive evaluation when a clinical problem was identi-
fied and did not undergo routine serial neuropsychological evaluation
during the disease course. Therefore, the recorded incidence of fron-
totemporal dysfunction in this cohort is likely to be an underestimate,
as prospective neuropsychological studies show a higher prevalence of
frontal lobe dysfunction in patients with ALS (Phukan et al., 2011).
Screening for the C9ORF72
hexanucleotide repeat sequence
by repeat primed polymerase chain
reaction
Genomic DNA (100 ng) was amplified using the primers and method
described by Renton et al. (2011) with a minor adjustment to the
primer ratio: Forward:Reverse:Anchor = 8:1:8. Detailed methodology
is provided in the Supplementary Material. Fragments were analysed
on an ABI3730 capillary analyser (Applied Biosystems, Life
Technologies Corporation) using a 60-s injection time. Fragment
data were analysed using Peak Scanner Software (Applied
Biosystems, Life Technologies Corporation).
Neuropathological evaluation
The brain and spinal cord tissues were donated to the Sheffield Brain
Tissue Bank for research, with the consent of the next of kin. The
donation procedure and use of the tissue in this project were under-
taken with research ethical committee approval. Tissue was available
for detailed pathological evaluation from 19 of the 22 brain
tissue bank cases with the hexanucleotide expansion of C9ORF72.
These cases were compared with up to 96 (see below and Table 3)
ALS cases, which were negative for the C9ORF72 expansion and three
neurologically normal controls. For some cases, one cerebral hemi-
sphere, half the midbrain and brainstem, a portion of the cerebellum
and segments of the spinal cord at various levels were rapidly frozen
in liquid nitrogen at autopsy and stored at 80C. The remainder of
the CNS was formalin-fixed. For the other cases, only a portion of
the cerebellum was frozen, and the whole brain and spinal cord
were formalin fixed. Selected blocks (including lumbar, thoracic and
cervical spinal cord, medulla, midbrain, hippocampus, and frontal,
temporal and motor neocortex) were processed to paraffin.
In addition to routine neurohistology with tinctorial preparations,
immunohistochemistry was performed for p62/sequestosome 1, TAR
DNA-binding protein 43 (TDP-43), FUS, OPTN, CD68 and C9ORF72
(Supplementary Table 1) where paraffin tissue was available. The latter
antibody is commercially available (Santa Cruz Biotechnology Inc.) and
was selected on the basis that it labelled a protein of the molecular
weight of C9ORF72 on western blotting (data not shown).
Immunohistochemistry was performed on all available cases with the
hexanucleotide expansion as well as three cases with sporadic ALS
without the expansion and three neurologically healthy controls.
To characterize the distribution of pathology in cases with ALS in the
Sheffield Brain Tissue Bank, the extent of p62-positive pathology was
assessed. In all regions assessed, a single 6-mm section was examined
and the number of neuronal cytoplasmic inclusions in the region of
interest assessed semi-quantitatively as 0–4 (low), 5–9 (intermediate)
or 10 or more (high). The regions of interest assessed were the anter-
ior horn of the spinal cord, at mid-cervical and lumbar levels; the
hypoglossal, dorsal vagal and ambiguus nuclei of the medulla; the
dentate granule cell layer and CA4 subregion of the hippocampus
and the frontal and motor cortices. In the cortical regions, quantifica-
tion of neuronal cytoplasmic inclusions was carried out in 10 fields
(25 objective).
In addition, the number of neuronal cytoplasmic inclusions in the
CA4 subregion of the hippocampus was assessed using the same
semi-quantitative scheme on sections that had been immunostained
for TDP-43 and OPTN.
Statistical methods
Differences between phenotypic characteristics of groups were deter-
mined by an independent-samples t-test. Differences between gender
ratios and site of onset and differences in the ubiquitylated neuronal
cytoplasmic inclusion load were calculated using a chi-squared (2)
test. A significance level of P5 0.05 was used for all tests.
Results
Genetic screening
ALS-associated pathological expansions in C9ORF72 have been
defined as 430 repeats, whereas the majority of controls have
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43 repeats (DeJesus-Hernandez et al., 2011; Renton et al.,
2011). In our cohort of 563 ALS cases, 62 (11%) ALS cases (27 fa-
milial ALS, 35 sporadic ALS) were found to have expansions 430
repeats (Fig. 1). The median number of repeats in ALS cases with-
out pathological expansions was four compared with five in con-
trols (Fig. 2). The length of a pathologically expanded repeat
(430 repeats) cannot be accurately quantified by repeat primed
polymerase chain reaction. This technique is only sufficient to
segregate individuals with large expansions 430 from those with-
out. An expanded repeat 430 was detected in two control cases
(2/361 = 0.6%), a 76-year-old male and a 46-year-old female,
neither of whom had any relevant past medical or family history.
Pathological expansions accounted for 27/63 (43%) of our
familial ALS index cases. Analysis of family trees of all index
cases revealed 13 families with a clear autosomal dominant pat-
tern of inheritance and we were able to demonstrate segregation
Figure 1 Graphical representation of fragments generated in repeat primed polymerase chain reaction displayed using Peak Scanner
Software. Individual peaks represent fragments of increasing length at 6 bp intervals, corresponding to single GGGGCC repeats; 280 bp is
minimum polymerase chain reaction product length. (A) Graph from a patient with ALS with a pathological expansion in C9ORF72
showing exponentially tailing series of peaks consistent with a repeat length430. (B) Graph from a patient with ALS without pathological
expansion showing repeat length of approximately four repeats.
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Figure 2 Graph showing the lengths of the GGGGCC hexanucleotide repeats in ALS cases (n = 563) and controls (n = 361); 62/563
(11%) of cases with ALS and 2/361 (0.6%) of control cases had repeat lengths of 430.
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of the expanded allele in one family with evidence of incomplete
penetrance (Fig. 3). In familial ALS cases with previously identified
mutations in SOD1, TARDBP, FUS, ANG, CHMP2B and VAPB, an
expanded C9ORF72 repeat 430 was identified in a case with an
p.Ala321Val mutation in TARDBP (Kirby et al., 2010) and also in a
case with a benign p.Gly174del alteration in FUS reported previ-
ously (Hewitt et al., 2010). An unreported case with a
p.Glu322Lys OPTN substitution also showed an expansion.
Pathological expansions were also present in 35/500 (7%) of
our cases with sporadic ALS. However, for 16/35 cases there was
either a family history of dementia or other neurological or neuro-
muscular disease; or at least one parent died before the age of
70 years. It is therefore likely that a proportion of these cases
represent unrecognized familial disease. For the remaining 19/35
sporadic ALS cases with the expansion, a complete family history
was available and in these cases there was no family history of
neurological disease and both parents lived into late old age.
Therefore, it is likely that these cases represent true sporadic
disease, although incomplete penetrance cannot be excluded.
DNA from parents of these apparently sporadic cases was not
available for analysis to confirm the occurrence of de novo
mutations.
Clinical features of ALS cases with
pathological expansions in C9ORF72
The clinical features of the cases with pathological expansions in
C9ORF72 are summarized in Table 1. The mean age of onset was
57.3 years (range 27–74 years). Of these, 60% of cases had limb
onset disease, 31% had bulbar onset disease; 6% had multi-focal
disease onset, one patient presented with dementia and for one
patient the time of onset was not known. The mean disease
duration from symptom onset in these patients was 30.5 months
(range 7–60 months); three patients are alive at the time of
writing and for one patient survival information was not available.
Clinical characteristics of patients with the C9ORF72 expansion
were compared with the remainder of the screened cohort
(Table 2). The C9ORF72 patients had a significantly lower age
at onset than non-C9ORF72 cases (mean age of onset
57.3 years, SD 8.9 years compared with mean 60.1 years, SD
12.3 years; P = 0.03, d.f. = 494, t = 2.20), but not significantly
different to the overall familial ALS cohort (P = 0.43, d.f. = 107,
t = 0.78). Likewise, patients with the C9ORF72 expansion had a
significantly shorter duration of disease than non-C9ORF72 cases
[mean (SD) duration of disease 30.5 (13.3 months) compared with
mean (SD) 36.3 (28.5 months); P = 0.01, d.f. = 397, t = 2.44] but
not significantly different to the overall familial ALS cohort
(P = 0.32, d.f. = 100, t = 1.00). The subgroup of patients with
sporadic ALS with the C9ORF72 expansion differed from patients
with familial ALS with the expansion, in that they had a signifi-
cantly higher age of onset [mean 59.5 (SD 7.0 years) in sporadic
ALS, 54.3 (SD 10.4 years) in familial ALS, P = 0.03, d.f. = 59,
t = 2.21], but no difference in age of onset to the screened
cohort overall. There was no difference between patients with
sporadic ALS and patients with familial ALS with the expansion,
with respect to duration of disease [mean (SD) 28.6 (12.0 months)
in sporadic ALS, and 33.3 (14.8 months) in familial ALS, P = 0.21,
d.f. = 56, t = 1.26].
In our cohort of patients with the C9ORF72 expansion, 5/27
(19%) familial ALS cases and 5/35 (14%) sporadic ALS cases had
evidence on clinical and neuropsychological testing of FTD.
An additional 12 cases had a family history of dementia in first-
or second-degree relatives, six of whom had familial ALS and six
of whom had sporadic ALS. Overall 22/62 (35%) of patients with
the expansion had either a personal diagnosis of dementia or a
family history of dementia in first- or second-degree relatives. In
this cohort, routine neuropsychological assessment was not per-
formed in the absence of a clinically apparent cognitive problem,
so subclinical cognitive dysfunction was not evaluated.
Several of the patients carrying the hexanucleotide expansion in
C9ORF72 were either diagnosed with or had a family history of
other non-dementia neurological or neuromuscular disease,
particularly neurodegenerative disease: four patients had a family
history of Parkinson’s disease and one patient had a comorbid
diagnosis of Parkinson’s disease that was confirmed at post-mor-
tem; thus 4/62 (6.5%) patients had either a diagnosis of
Parkinson’s disease or a family history of Parkinson’s disease.
Two patients had evidence of demyelinating disease and one
further patient had a family history of multiple sclerosis; thus
3/62 (5%) patients had either a diagnosis or a family history of
demyelinating disease. Other noteworthy findings included a
patient with a family history of ALS, Charcot–Marie–Tooth disease
and dementia; one patient with early onset cataracts which also
occurred in his mother; one patient with a family history of
Huntington’s disease and one patient with a brother who died
with a diagnosis of muscular dystrophy.
+
+
+
-
Probable ALS
70yrs
48yrs
64yrs
-
68yrs >70yrs
Figure 3 Family tree from a familial ALS case with the
hexanucelotide repeat sequence in C9ORF72. The expansion
segregated with disease in two cases and was present in an
obligate carrier. + = carrier of expansion,  = confirmed ab-
sence of the expansion. Current age or age of death is shown
where information was available.
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Table 1 Summary of phenotypic information from patients with the hexanucleotide repeat expansion of C9ORF72
Patient Sex Age at
onset
(years)
Duration of
disease
(months)
Site of
onset
Variant
of
disease
Family
history
Cognitive
impairment
Family history and other noteworthy features
Brain Tissue Bank
1 Male 69 26 Limb ALS Familial None Autosomal dominant pattern of familial ALS
2 Female 59 40 Limb ALS Familial None Autosomal dominant pattern of familial ALS
3 Male 42 50 Limb ALS Familial None Autosomal dominant pattern of familial ALS
4 Male 66 14 Bulbar ALS Familial NA Autosomal dominant pattern of familial ALS
5 Male 64 31 Limb ALS Familial Undefined
dementia
Nephew is Patient 27.
6 Female 62 24 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS.
Patient diagnosed with multiple sclerosis. Benign
polymorphism Gly174del in FUS/TLS.
7 Female 56 43 Limb ALS Familial Diagnosed
FTD
Maternal family history of ALS, Charcot–Marie–Tooth
and early onset undefined dementia.
8 Female 50 28 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS. Patient
carries a p.Glu322Lys substitution in OPTN
9 Male 47 19 Multi-focal ALS Familial None Autosomal dominant pattern of familial ALS. Patient
and his father diagnosed with Parkinson’s disease.
10 Female 63 43 Cognitive ALS Familial Diagnosed
FTD
Mother diagnosed with early onset undefined
dementia. Brother diagnosed with ALS.
11 Female 61 58 Limb ALS Familial None Two sisters diagnosed with ALS
12 Female 65 12 Bulbar ALS Sporadic None
13 Female 67 26 Limb NA Sporadic None
14 Male 63 11 Limb ALS Sporadic None
15 Male 56 13 Bulbar ALS Sporadic None
16 Female 61 40 Bulbar ALS Sporadic Undefined
dementia
17 Female 58 7 Limb ALS Sporadic None
18 Female 61 42 Limb ALS Sporadic None
19 Male 62 20 Bulbar ALS Sporadic None
20 Male 45 14 Limb ALS Sporadic None
21 Female 51 38 Multifocal ALS Sporadic None
Blood DNA Biobank
22 Female 47 18 Limb ALS Familial Diagnosed
FTD
Autosomal dominant pattern of familial ALS
23 Male 61 38 Limb ALS Familial None Brother and sister diagnosed with ALS. Father
diagnosed with Huntington’s disease.
24 Female 27 14 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS.
Maternal family history of AD; paternal family
history of undefined dementia.
25 Female 50 18 Bulbar ALS Familial Undefined
dementia
Father diagnosed with FTD-ALS. Autosomal
dominant pattern of familial ALS
26 Female 48 52 Limb ALS Familial None Brother diagnosed with ALS. Maternal aunt
diagnosed with Alzheimer’s disease. Patient notably
athletic.
27 Male 48 ALIVE Bulbar ALS Familial None Maternal uncle is Patient 5. Maternal grandmother
diagnosed with early onset dementia.
28 Female 61 22 Limb ALS Familial None Autosomal dominant pattern of familial ALS
29 Female 44 43 Bulbar ALS Familial None Autosomal dominant pattern of familial ALS
30 Female 61 43 Bulbar NA Familial None Paternal uncle diagnosed with ALS. Father diagnosed
with Parkinson’s disease.
31 Female 64 ALIVE Limb ALS Familial None Brother diagnosed with ALS. Paternal grandfather
diagnosed with undefined dementia.
32 Female 45 34 Bulbar ALS Familial NA Autosomal dominant pattern of familial ALS. Mother
diagnosed with FTD-ALS. Maternal grandmother
diagnosed with multiple sclerosis.
33 Male 51 17 Limb ALS Familial None Sister diagnosed with FTD-ALS. Patient and mother
diagnosed with early onset cataracts.
34 Male 65 52 Limb ALS Familial None Nephew diagnosed with ALS. Patient notably athletic
35 Male 63 13 Multifocal ALS Familial None Paternal aunt diagnosed with ALS
36 Female NA NA NA NA Familial NA
37 Female 37 58 Limb ALS Familial None Mother probable ALS. Patient has pAla321Val
mutation in TARDBP
38 Male 56 24 Limb ALS Sporadic None
(continued)
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The patients with C9ORF72 expansion had limb onset disease
in 37/62 (60%) cases and bulbar onset disease in 19/62 (31%
cases) (Table 2). These proportions are similar to those for the
cohort without the C9ORF72 expansion (56 and 25%, respect-
ively). There was no significant difference in gender ratio
(P = 0.09, d.f. = 1, 2 = 2.85) or site of onset (P = 0.74, d.f. = 1,
2 = 0.10) between the two groups although the patients
with familial ALS with the expansion had a female preponderance
(ratio males:females = 1:1.7), which was not present in the
patients with sporadic ALS with the expansion (males:
females = 1.1:1) or the screened cohort overall (males:females =
1.3:1).
Table 1 Continued
Patient Sex Age at
onset
(years)
Duration of
disease
(months)
Site of
onset
Variant
of
disease
Family
history
Cognitive
impairment
Family history and other noteworthy features
39 Male 56 41 Limb ALS Sporadic None
40 Female 66 32 Bulbar ALS Sporadic None Father died of undefined dementia
41 Male 60 35 Bulbar ALS Sporadic Undefined
dementia
Mother diagnosed with Alzheimer’s disease
42 Female 50 27 Limb ALS Sporadic None Father diagnosed with early onset dementia.
43 Male 60 32 Limb ALS Sporadic None Mother diagnosed with early onset dementia. Patient
notably athletic.
44 Male 43 40 Limb ALS Sporadic None Patient notably athletic.
45 Male 64 28 Limb ALS Sporadic None
46 Male 74 36 Limb ALS Sporadic None Father and sister diagnosed with undefined dementia.
47 Male 58 60 Limb ALS Sporadic None Onset coincided with carpal tunnel syndrome
therefore difficult to determine exact date.
48 Female 57 20 Limb ALS Sporadic None Demyelination noted on MRI of CNS.
49 Female 62 24 Limb ALS Sporadic None Maternal aunt diagnosed with Alzheimer’s disease.
Patient notably athletic
50 Female 57 21 Multifocal ALS Sporadic None
51 Male 60 27 Bulbar ALS Sporadic None
52 Male 63 ALIVE Limb ALS Sporadic Undefined
dementia
Brother and father diagnosed with schizophrenia
53 Male 61 24 Limb ALS Sporadic None Mother diagnosed early onset Alzheimer’s disease
and Parkinson’s disease. Patient notably athletic.
54 Male 51 21 Bulbar ALS Sporadic None Previous poliomyelitis which left him with wasted
right leg
55 Male 50 27 Bulbar ALS Sporadic None
56 Female 59 22 Limb ALS Sporadic Undefined
dementia
57 Female 71 24 Limb ALS Sporadic Diagnosed
FTD
58 Female 65 40 Limb ALS Sporadic None Patient notably athletic.
59 Female 52 24 Limb ALS Sporadic NA
60 Female 63 28 Bulbar ALS Sporadic NA
61 Female 71 57 Limb ALS Sporadic None Cousin diagnosed with Parkinson’s disease
62 Male 65 36 Limb ALS Sporadic None Brother suffered muscular dystrophy
NA = data not available.
Table 2 Comparison of phentotypic information from patients the hexanucleotide repeat expansion of C9ORF72 and the
overall screened cohort
Phenotype C9ORF72
cases (n = 62)
C9ORF72 sporadic
ALS cases (n = 35)
C9ORF72 familial ALS
cases (n = 27)
Non-C9ORF72 ALS cases in the
screened cohort (n = 501)
Mean (SD) age of onset (years) 57.3 (8.9) 59.5 (7.0) 54.3 (10.4) 60.1 (12.3)
Mean (SD) disease duration (months) 30.5 (13.3) 28.6 (12.0) 33.3 (14.8) 36.3 (28.5)
Limb onset (%) 60 66 51 56
Bulbar onset (%) 31 29 34 25
Gender ratio (males:females) 1:1.2 1.1:1 1:1.7 1.3:1
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Neuropathological features
All cases with the hexanucleotide repeat expansion of C9ORF72
showed the classical molecular pathology of ALS (Figs 4 and 5).
There was a marked loss of lower motor neurons in the anterior
horns of the spinal cord and cranial nerve motor nuclei in the
medulla. Bunina bodies were present in some residual motor
neurons. All cases showed a moderate to marked microglial reac-
tion on CD68 immunohistochemistry in the pyramidal tract at all
levels (white matter underlying motor cortex, mid-crus cerebri,
Figure 4 Histological examination of cases with the C9ORF72 hexanucleotide repeat expansion reveals: depletion of motor neurons from
the anterior horns of the spinal cord (A) with Bunina bodies (arrow) in residual neurons (B); Microglial activation in lateral corticospinal
tracts (arrowheads, C); ubiquitylated neuronal (skein-like in D and compact in E) and glial (F) cytoplasmic inclusions in the anterior horns of
the spinal cord; (G) TDP-43 positive skein-like neuronal cytoplasmic inclusions (arrows) and pre-inclusions (arrowhead) in the anterior
horns of the spinal cord; (H) OPTN positive neuronal cytoplasmic inclusion in the anterior horns of the spinal cord; (I) ubiquitylated
neuronal (arrow) and glial (arrowhead) cytoplasmic inclusions in the motor cortex; TDP-43 positive neuronal cytoplasmic inclusion in
the motor cortex (arrow, J); ubiquitylated neuronal cytoplasmic inclusions (arrows) in the CA4 subfield of the hippocampus (K) and
frontal neocortex (L). Lower power view of hippocampal CA4 subfield with adjacent dentate gyrus granule cells (left) reveals neuronal
cytoplasmic inclusions (arrows) in CA4 of a case of ALS with C9ORF72 hexanucleotide repeat expansion (M) and none in a case without
this expansion (N). Preparations: haematoxylin and eosin, A and B; CD68, C; p62, D–F, I, K–N; TDP-43, G and J; optineurin, H.
Scale bar = 20 mm (B and F); 30 mm (D, E, G and H–L); 60 mm (A, M and N); 500mm (C).
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medullary pyramids, and lateral and anterior corticospinal tracts)
indicating corticospinal tract degeneration.
Immunohistochemistry for p62 revealed neuronal and glial cyto-
plasmic inclusions in the anterior horns of the spinal cord, cranial
nerve motor nuclei and motor cortex. These were also detectable
using both TDP-43 and OPTN immunohistochemistry. Results of
the quantitation of neuronal cytoplasmic inclusions using p62
immunohistochemistry are presented in Table 3. In general
terms, there was a significantly higher load of neuronal cytoplas-
mic inclusions in all regions in individuals with the C9ORF72
repeat expansion compared with ALS cases without this
expansion.
The most striking feature of cases bearing the C9ORF72 hex-
anucleotide expansion was the degree of extra-motor p62 positive
neuronal cytoplasmic inclusion pathology in contrast to the relative
paucity of this finding in cases without the expansion. This feature
was most pronounced in the CA4 and CA3 subregions of the
hippocampus and, to a lesser extent, the frontal neocortex and
dentate gyrus of the hippocampus. To avoid potential bias,
hippocampal and frontal neocortex slides prepared for p62
immunohistochemistry from 11 cases with and 11 cases without
the expansion were randomly selected and reassessed blind to
case identity and C9ORF72 gene status. For the frontal neocortex,
low, intermediate and high levels of neuronal cytoplasmic
inclusions were seen in 0, 1 and 10 cases with the expansion
and 10, 1 and 0 cases without the expansion, respectively
(2 = 20, d.f. = 2, P50.0005). For the dentate fascia of the
hippocampus, low, intermediate and high levels of cytoplasmic
inclusions were seen in 3, 1 and 7 cases with the expansion and
9, 0 and 2 cases without the expansion, respectively (2 = 6.778,
d.f. = 2, P = 0.034). For the CA4 subfield of the hippocampus,
high levels of neuronal cytoplasmic inclusions were seen in all 11
cases with the hexanucleotide expansion and low levels in all 11
cases without the expansion (2 = 22.000, d.f. = 1, P50.0005).
The slides were assessed independently by a second neuro-
pathologist who assigned all 22 cases correctly into groups with
Figure 5 Immunohistochemistry for C9ORF72 shows similar features in neurologically healthy controls and individuals with motor neuron
disease with and without the hexanucleotide repeat expansion. The spinal cord stained with C9ORF72 antibody shows: (A) Coarse
granular staining of the spinal cord anterior horn neuropil with variable cytoplasmic labelling of motor neurons (arrow) and perinuclear
labelling of small glial cells (e.g. arrowhead); patches of more intense labelling (arrowheads) on the surfaces of some motor neurons (B)
that is often more marked in neuronal processes (C). In white matter (dorsal column) there is staining around axons corresponding to
portions of myelin sheath (D). Granular staining of the neuropil with more prominent ‘streaks’ and only pale neuronal expression is seen in
the hippocampus (CA4 subregion with dentate gyrus granule cell layer top right; E). Granular neuropil labelling with lesser staining of
neurons is also seen in the neocortex (frontal cortex; F). Scale bar = 20 mm (B and F); 30 mm (A–D); 60 mm (E and F).
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and without the hexanucleotide expansion on the basis of
p62-immunoreactive pathology in the CA4 hippocampal subfield.
There was thus 100% inter-rater agreement between the assess-
ments of the two observers. Next, the proportion of the neuronal
cytoplasmic inclusion pathology seen in the hippocampus that was
detected by TDP-43 and OPTN immunohistochemistry was inves-
tigated (Table 4). This was markedly less than was seen on p62
immunohistochemistry; in the CA4 subregion, OPTN antibodies
detect greater numbers of inclusions than TDP-43 antibodies.
The converse is true for the dentate gyrus.
The hippocampal and neocortical p62 labelling took the form
of neuronal and glial inclusions in all cortical layers with very
few dystrophic neurites, corresponding to Type B according to
the harmonized classification system for FTLD-TDP pathology
(Mackenzie et al., 2011).
A single case with the hexanucleotide repeat expansion showed
combined ALS and multiple sclerosis pathology. This case had pre-
viously been demonstrated to also have a benign polymorphism
(p.Gly174del) in the gene FUS and has been described elsewhere
(see Case 4, Hewitt et al., 2010).
Immunohistochemistry for C9ORF72 revealed fine punctate
staining throughout the grey matter structures of the CNS.
Neuronal cell bodies showed only pale to moderate intensity of
staining. There were occasional patches of staining on the cell
membrane that was more prominent on axonal hillocks.
Neuronal nuclei were negative for C9ORF72. This pattern of stain-
ing was reminiscent of that seen in preparations for synaptic
markers. There was positive staining of smaller glial cells, mostly
having the appearance of oligodendrocytes. In white matter tracts,
there was partial circumferential staining around axons, with some
Table 3 Numbers of cases with low, intermediate and high levels of neuronal cytoplasmic inclusion pathology in cases with
and without the C9ORF72 hexanucleotide repeat expansion in different regions of the CNS
C9ORF72 repeat expansion Total number of cases Per cent Chi-squared test
Low Intermediate High Total Low Intermediate High 2 d.f. P-value
Lumbar cord anterior horns
Present 3 6 7 16 19 38 44 23.657 2 50.0005
Absent 32 10 1 43 74 23 2
Cervical cord anterior horns
Present 7 5 3 15 47 33 20 6.243 2 0.044
Absent 32 6 2 40 80 15 5
Medulla motor nuclei
Present 8 1 6 15 53 7 40 7.800 2 0.02
Absent 12 3 0 15 80 20 0
Dentate gyrus of hippocampus
Present 0 0 17 17 0 0 100 36.780 2 50.0005
Absent 66 8 22 96 69 8 23
Hippocampus CA4 subfield
Present 0 0 17 17 0 0 100 67.501 1 50.0005
Absent 93 0 0 93 100 0 0
Frontal neocortex
Present 0 1 18 19 0 5 95 74.495 2 50.0005
Absent 92 1 1 94 98 1 1
Table 4 Numbers of cases with C9ORF72 hexanucleotide repeat showing low, intermediate and high numbers of neuronal
cytoplasmic inclusions in the hippocampal dentate gyrus granule cell layer and CA4 subfields using immunohistochemistry
for p62, TDP-43 and OPTN
CNS region p62, n (%) TDP-43, n (%) OPTN, n (%)
Dentate gyrus
Low 0 (0) 10 (58.8) 13 (81.25)
Intermediate 0 (0) 3 (17.6) 2 (12.5)
High 17 (100) 4 (23.5) 1 (6.25)
CA4
Low 0 (0) 15 (88.2) 4 (25)
Intermediate 0 (0) 1 (5.9) 2 (12.5)
High 17 (100) 1 (5.9) 10 (62.5)
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granularity to the staining pattern. In the hippocampal pyramidal
cell layer, there was coarse staining of the neuropil that was most
intense in the CA4 and CA3 subfields. The intensity of this staining
was much less marked in CA2 and CA1. In the hippocampus, the
intense C9ORF72 labelling was seen in the same regions that also
demonstrated ubiquitylated neuronal cytoplasmic inclusions.
However, no difference in the pattern of immunostaining for
C9ORF72 was observed between cases with and without the
hexanucleotide expansion or in the neurologically healthy control
cases.
Discussion
In keeping with the recent reports (DeJesus-Hernandez et al.,
2011; Renton et al., 2011), we find significant variability in the
presentation of ALS in patients carrying the C9ORF72 hexanucleo-
tide expansion so that patients with the expansion manifest the
full range of the known ALS phenotype. In addition, we have
identified a number of interesting associations between ALS and
other neurological diseases in this group of patients. This may
suggest that the effect of C9ORF72 expansions is modified by
other genetic or environmental factors to produce variability in
the ALS phenotype and even in the area of the nervous system
affected. Importantly, we find that with the exception of the gran-
ule cells of the dentate fascia, carriers of the C9ORF72 hexanu-
cleotide repeat expansion account for the extra-motor pathology
in our series.
Patterns of inheritance
Hexanucleotide expansions of C9ORF72 account for a large
proportion (43%) of familial ALS cases in our cohort from the
North of England and many of these families exhibit clear auto-
somal dominant inheritance. The high incidence of the C9ORF72
repeat expansions in apparently sporadic cases is an important
observation to explain. It may represent a genuinely inherited
pathogenic genotype with variable penetrance or it may represent
a high rate of new mutation consistent with the suggestion that
the C9ORF72 gene may be inherently unstable (Renton et al.,
2011). That incomplete penetrance can occur is demonstrated
by a family within our cohort where the expansion is present in
the index case and his maternal uncle who are both patients with
ALS, and in the mother of the index case who is disease free into
old age (Fig. 3). It is noteworthy that for a proportion of the
apparently sporadic cases there is a family history of neurological
disease; it seems likely that some of these cases represent unrec-
ognized or undisclosed familial disease. In particular, some of the
patients with relatives who developed dementia may in fact have
familial ALS/FTD. It is interesting that, with regard to age of onset
and gender ratio but not disease length, the patients with sporadic
ALS with the C9ORF72 expansion are distinct from the patients
with familial ALS with the expansion. The earlier age of onset of
familial ALS cases with the mutation may suggest the occurrence
of genetic anticipation, although this could not be confirmed in
this study as the precise length of the pathological repeat
sequences has not yet been determined.
Of note, we have now identified a pathogenic change in 42/63
(67%) of our familial cohort. In two cases, an expansion in
C9ORF72 was found to coexist with another identified putative
mutation linked to ALS. That the expansion was absent from most
of our patients with a previously identified mutation is supportive
of the independent pathogenesis of those changes. An expansion
was found in one case (Patient 37) who had a p.Ala321Val
change in TARDBP. The pathogenesis of mutations in the
C-terminal region of TARDBP is well established (Sreedharan
et al., 2008; Kirby et al., 2010) and it is notable that the remain-
der of patients in our cohort with described changes in TARDBP
did not carry the C9ORF72 expansion. It is interesting that the age
of onset in this patient was relatively young (37 years), perhaps
consistent with a synergistic effect of both genetic changes on the
disease pathogenesis. However, the disease duration in this patient
was relatively long at 58 months. Since mutations in TARDBP
and expansions of C9ORF72 are both associated with neuronal
cytoplasmic TDP-43 inclusions, it is conceivable that they may
be affecting the same pathway in a non-additive manner.
Unfortunately, no post-mortem material was available from
this case.
An unreported familial ALS case with a p.Glu322Lys OPTN sub-
stitution also showed a C9ORF72 expansion. While this substitu-
tion has been reported as a polymorphism in sub-Saharan African
samples (Liu et al., 2008), it was absent from 375 neurologically
normal Caucasian controls from the same geographical region.
This patient had bulbar onset ALS, with onset of disease aged
50 years and a disease course of 29 months.
Dementia
An association between ALS and FTD is well established (Phukan
et al., 2007). However, a previous population study reported that
the incidence of dementia (5%) in relatives of patients with ALS
was only slightly higher than in controls (Huisman et al., 2011)
and only in first-degree relatives. ALS is thought to be the
common end-point of various disease mechanisms (Ferraiuolo
et al., 2011) and it is possible that only some of these mechanisms
result in an associated dementia. Thus, disease heterogeneity may
have meant that a stronger association in some patients within this
population study was masked by a lack of association in other
patients. In our cohort of patients with an expansion in
C9ORF72, 35% either had a diagnosis of dementia or a family
history of dementia. We propose that the subtype of ALS caused
by hexanucleotide repeat expansions of C9ORF72 shows a striking
association with dementia clinically. This proposal is strongly
supported by our finding of extra-motor neuropathology in all
C9ORF72 expansion cases examined at autopsy, in combination
with a relative paucity of extra-motor pathology in cases found to
have normal repeat lengths of C9ORF72. This hypothesis would
be supported further by routine cognitive testing of ALS cases
during life, with subsequent correlation with post-mortem neuro-
pathology. The TDP-43 proteinopathies ALS, ALS with FTLD and
pure FTLD-TDP have often been seen as a continuum of disease
at both the clinical (Lillo and Hodges, 2009) and pathological
levels (Mackenzie and Feldman, 2005; Geser et al., 2009). This
has raised the question of what governs where on this spectrum
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a patient with a TDP-43 proteinopathy will manifest disease
pathologically, and how they will present clinically. Our data sug-
gest that repeat expansions of C9ORF72 have a strong influence
on the clinical phenotype and the spectrum of pathology. The
precise mechanism(s) by which the repeat expansion has this
effect needs to be elucidated, and it will clearly be of interest
to compare the distribution of pathology in brains of FTLD-TDP
cases with and without the repeat expansion.
Other neurological disease
Several of the patients carrying the hexanucleotide expansion in
C9ORF72 were either diagnosed with or had a family history of
other neurological, particularly neurodegenerative disease. This is
illustrated by the case with both ALS and multiple sclerosis
confirmed at autopsy. Previous work has suggested that the
clinical spectrum of ALS may be wider than initially recognized.
In particular, mutations in the VCP gene appear to cause a clinical
spectrum including inclusion body myositis, FTD and Paget’s
disease (Johnson et al., 2010). ALS has also been reported to
coexist with glaucoma in a patient with a mutation in the OPTN
gene, although the authors went on to suggest that this may have
been a coincidence (Maruyama et al., 2010). Analysis of our
cohort suggests that expansion of C9ORF72 may also produce a
broad clinical phenotype although we have not yet demonstrated
segregation of the expansion with non-ALS neurological disease.
A previous population study on the Island of Guam described
coexistence of Parkinson’s disease and ALS both within individuals
and within families (Yanagihara et al., 1983). However, the results
of other population studies investigating the coexistence of more
than one neurodegenerative disease have been inconsistent.
A recent population-based study suggested that the rate of
Parkinson’s disease among relatives of patients with ALS was
not significantly different from controls (Huisman et al., 2011).
However, it is noteworthy that among our patients with the hex-
anucleotide repeat sequence, the frequency of Parkinson’s disease
in relatives (6.5%) is much higher than in either the disease or
control population from the Huisman study (0.9%). One of our
patients with the C9ORF72 expansion was diagnosed with both
Parkinson’s disease and ALS. His Parkinson’s disease developed
at a relatively early age of 38 years but was otherwise clinically
typical, showing a good response to L-DOPA therapy; he had a
deep brain stimulator inserted aged 47 years. Post-mortem he had
neuropathological features of both Parkinson’s disease and ALS
including cell loss from the substantia nigra and 6/6 Braak grade
-syncluclein pathology with substantial staining both in the
substantia nigra and in neocortical regions.
The coexistence of multiple sclerosis and ALS has been previ-
ously reported (Hader et al., 2008; Ismail et al., manuscript
under review) and an increased incidence of multiple sclerosis in
the offspring of patients with ALS has also been reported
(Hemminki et al., 2009). The association of patients with ALS
with the C9ORF72 expansion and multiple sclerosis in our
cohort is consistent with these reports and raises the possibility
that the association between ALS and multiple sclerosis may be
related to this genotype. The diagnosis of Huntington’s disease in
the father of a patient carrying the C9ORF72 expansion is
especially interesting given that Huntington’s disease is also related
to an aberrant repeat sequence. Perhaps a common underlying
mechanism has led to the de novo occurrence of nucleotide
repeat sequences in both of these individuals.
Neuropathological features
Qualitatively, the neuropathological features associated with
hexanucleotide repeat expansion of C9ORF72 are those of clas-
sical ALS with ubiquitylated, TDP-43 and OPTN positive neuronal
and glial cytoplasmic inclusions in upper and lower motor neurons
as well as glia. This is seen in combination with Bunina bodies and
degeneration of the pyramidal tracts. What is striking is the
association of pyramidal cell pathology with the expansion in the
hippocampus and frontal neocortex, while very little such path-
ology is seen in ALS cases without the repeat expansion. This
differentiation is less marked in the context of the granule cells
of the hippocampal dentate gyrus, a structure that is generally
believed to be one of the most sensitive extra-motor structures
to TDP-43 proteinopathy (Mackenzie and Feldman, 2003; Takeda
et al., 2009). The extra-motor pathology seen is best characterized
as type B according to the scheme of Mackenzie et al. (2011).
The subdivision of ALS cases into two subgroups on the basis of
neuropathological involvement of extra-motor (principally hippo-
campal and frontotemporal neocortex) has been described
elsewhere (Nishihira et al., 2008). Data presented in this report
indicate that repeat expansions in C9ORF72 represent a major
molecular basis for this pathological dichotomy.
It appears from our data derived from a large pathological
cohort of ALS autopsies that the finding of extra-motor neocortical
pathology, in particular ubiquitylated neuronal cytoplasmic inclu-
sions in the CA4 subfield of the hippocampus is a relatively reliable
indicator of the presence of a hexanucleotide repeat expansion in
C9ORF72. Given that these changes can be detected at autopsy
with relative ease, this neuropathological feature may be used to
guide genetic investigation for the repeat expansion and thereby
inform genetic counselling and further research. Interestingly,
along with the characteristic hyaline conglomerate inclusions
found in some patients with SOD1 mutations (Ince et al.,
1998), this report adds another important element to neuropatho-
logical predictors of genotype in ALS. It is also noteworthy that
in the hippocampus, the majority of the neuronal cytoplasmic
inclusion pathology that is evident on p62 immunohistochemistry
is not apparent on TDP-43 immunohistochemistry. In fact, for the
CA4 subregion (where pathology is most specific for the repeat
expansion), OPTN is a more sensitive marker than TDP-43,
although neither is as sensitive as p62. This raises the significant
issue of what protein forms the ubiquitylated lesion in the majority
of these neurons if it is not TDP-43.
Immunohistochemistry to C9ORF72 protein reveals multiple
minute, puncta of labelling throughout the neuropil of grey
matter structures having the appearance of synaptic labelling in
neuronal processes. In this hippocampus, this is most marked in
the regions that show pathology that is specific for the hexanu-
cleotide repeat expansion. There is additionally labelling of glial
cells, many of which appear to be oligodendrocytes, and around
axons, corresponding to some regions of myelin. These constitute
762 | Brain 2012: 135; 751–764 J. Cooper-Knock et al.
 at U
niversity College London on June 14, 2013
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
initial observations, and the precise nature of C9ORF72 expression
requires more detailed characterization, including finer localization
studies, in order to begin to understand the function of the
C9ORF72 protein in the CNS.
Potential mechanism of neurodegen-
eration in C9ORF72-related ALS
ALS and FTD now join a growing number of neurodegenerative
disorders caused by expansions in repeat regions. In diseases
such as Huntington’s disease where the expansion is located in a
coding region and is translated, the mechanism leading to neuro-
degeneration seems to be clear; toxic accumulation of the mutant
protein that subsequently disrupts a variety of cellular processes.
However, in other diseases, such as myotonic dystrophy type 1
and several of the spinocerebellar ataxias, as in C9ORF72, the
pathological expansion is located in a non-coding region of the
gene, suggesting that the RNA species itself may be toxic. Several
lines of evidence are developing as to how RNA toxicity may be
mediated (Todd and Paulson, 2009). In myotonic dystrophy type
1, the mutant RNA has been shown to sequester several splicing
factors. This results in the formation of RNA foci within the cell
nucleus and also leads to downstream messenger RNA splicing
defects that are responsible for the features of muscle fibre atro-
phy and insulin resistance found in these patients (Fugier et al.,
2011). Consistent with this as a potential mechanism occurring in
ALS/FTD cases with expansions in C9ORF72, DeJesus-Hernandez
et al. (2011) demonstrated the presence of increased numbers of
neuronal RNA foci in ALS cases with the expansion. Additionally,
levels of C9ORF72 protein in lymphoblastoid cell lines and frontal
cortex samples taken from patients with FTD with pathological
expansions were not significantly different to those from patients
with FTD without expansions (DeJesus-Hernandez et al., 2011).
The splicing factor sequestration hypothesis also links C9ORF72
expansions to the TDP-43 pathology present in these cases; the
latter being implicated in alternative splicing of multiple transcripts
(Buratti and Baralle, 2001; Bose et al., 2008). However, to date
little is known about the function of the C9ORF72 protein and it
remains possible that defective splicing of its own messenger RNA
or transcriptional silencing resulting in haploinsufficiency, might
contribute to the neurodegenerative process.
Conclusion
This is the first detailed report of the clinical and pathological
phenotypes in a large cohort of 62 ALS/MND cases with patho-
logical hexanucleotide expansions in the C9ORF72 gene. This gen-
etic variant is common, accounting for 43% of familial ALS and
7% of sporadic ALS cases in this Caucasian cohort from Northern
England. Clinical features of note include the prevalence of
dementia in the ALS cases and close family members, and a
younger age of onset and more rapid disease progression com-
pared with other ALS/MND subtypes. Pathologically, these cases
showed classical ALS changes, with TDP-43 positive inclusions.
Extra-motor system pathology was strikingly over-represented in
the C9ORF72 positive cases, suggesting that this genotype may
be one predictor of an individual ALS patient’s location along the
anatomical spectrum of ALS pathology. Neuronal cytoplasmic
inclusions within the CA4 hippocampal region may be sufficiently
characteristic to allow prediction of mutation status.
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